Is there a role yet for new direct oral anticoagulants in cancer patients?

Abstract

Get full access to this article

View all access options for this article.

References

Wharin

Tagalakis

. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Rev 2014; 28: 1–8.

Akl

Kahale

Barba

. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014; 7: CD006650–CD006650.

Wells

Forgie

Rodger

. Treatment of venous thromboembolism. JAMA 2014; 311: 717–728.

Bauersachs

Berkowitz

Brenner

. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510.

Buller

Prins

Lensin

. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297.

Agnelli

Buller

Cohen

. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.

Agnelli

Buller

Cohen

. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708.

Hokusai

VTEI

Buller

Decousus

. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406–1415.

Schulman

Kearon

Kakkar

. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.

10.

Schulman

Kearon

Kakkar

. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709–718.

11.

Vedovati

Germini

Agnelli

. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147: 475–483.

12.

Cohen

Spiro

Buller

. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011; 31: 407–416.

13.

Goldhaber

Leizorovicz

Kakkar

. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365: 2167–2177.

14.

Levine

Liebman

. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10: 807–814.

15.

Gerotziafas

Mahe

Elalamy

. New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag 2014; 10: 423–436.